Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects

被引：30

作者：

Bratsos, Sosipatros ^{[1
]}

机构：

[1] Imperial Coll London, Cardiol, London, England

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2019年 / 11卷 / 08期

关键词：

rivaroxaban; pharmacokinetics; FACTOR-XA INHIBITOR; IN-VITRO; PHARMACODYNAMICS; BAY-59-7939; SAFETY; RATS; METABOLISM; ABSORPTION; VIVO; FOOD;

D O I：

10.7759/cureus.5484

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Direct oral anticoagulants (DOACs) have predictable pharmacokinetics and pharmacodynamics, limited potential for drug to drug interactions, and can be given at fixed doses without the need for routine coagulation monitoring, which makes them a very attractive alternative to vitamin K antagonists. DOACs act by specifically targeting a single coagulation factor, such as Factor Xa or thrombin. Rivaroxaban is a direct Factor Xa inhibitor and has been approved for use in several thromboembolic disorders, such as the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adult patients. This review aimed to provide an overview of the mechanism of action of rivaroxaban and outline its pharmacokinetic properties (absorption, distribution, metabolism, and excretion) in healthy adult subjects.

引用

收藏

页数：6

相关论文

共 25 条

[11] Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects [J].

Kubitza, Dagmar ;

Becka, Michael ;

Zuehlsdorf, Michael ;

Mueck, Wolfgang .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02) :218-226

[12] The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor [J].

Kubitza, Dagmar ;

Becka, Michael ;

Roth, Angelika ;

Mueck, Wolfgang .

JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03) :249-255

[13] Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor [J].

Kubitza, Dagmar ;

Becka, Michael ;

Mueck, Wolfgang ;

Halabi, Atef ;

Maatouk, Haidar ;

Klause, Norbert ;

Lufft, Volkmar ;

Wand, Dominic D. ;

Philipp, Thomas ;

Bruck, Heike .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) :703-712

[14] In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans [J].

Lang, D. ;

Freudenberger, C. ;

Weinz, C. .

DRUG METABOLISM AND DISPOSITION, 2009, 37 (05) :1046-1055

[15]

Mueck W, 2007, INT J CLIN PHARM TH, V45, P335

[16] Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban [J].

Mueck, Wolfgang ;

Stampfuss, Jan ;

Kubitza, Dagmar ;

Becka, Michael .

CLINICAL PHARMACOKINETICS, 2014, 53 (01) :1-16

[17] Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects [J].

Mueck, Wolfgang ;

Kubitza, Dagmar ;

Becka, Michael .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (03) :455-466

[18] In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor [J].

Perzborn, E ;

Strassburger, J ;

Wilmen, A ;

Pohlmann, J ;

Roehrig, S ;

Schlemmer, KH ;

Straub, A .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) :514-521

[19] Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy [J].

Preissner, Sarah C. ;

Hoffmann, Michael F. ;

Preissner, Robert ;

Dunkel, Mathias ;

Gewiess, Andreas ;

Preissner, Saskia .

PLOS ONE, 2013, 8 (12)

[20] The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants [J].

Samama, Meyer Michel .

THROMBOSIS RESEARCH, 2011, 127 (06) :497-504